Omega-3-carboxylic acids
As of the edition of 20 October 2026, Omega-3-carboxylic acids is a drug: marketed, first approved in 2014 (US); US protection ends in 2033.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Unknown
- Brand name
- Epanova
- First approved
- 5 May 2014 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- AstraZeneca
- Registered trials
- 15, 0 stopped early
- Disease areas
- Nutrition and metabolism; Digestive system; Heart and blood vessels; Hormones
US protection
US protection ends in 2033.
The last listed US drug-substance patent ends in 2033. The application that gives this date is held by AstraZeneca.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 7 | 7 | 0 | 0 |
| All trials | 15 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Originator and Lead sponsor of trials | 2011 to now |